论文部分内容阅读
表皮生长因子受体(EGFR)在多种实体瘤中表达,与肿瘤的发生和发展密切相关。necitumumab为一全人源化IgG1_κ单克隆抗体,与表皮生长因子竞争结合部位,阻滞表皮生长因子与其受体结合,抑制EGFR依赖性肿瘤的生长。necitumumab已获美国食品和药物管理局批准联合吉西他滨和顺铂用于转移性鳞状非小细胞肺癌的一线治疗。常见的不良反应包括皮疹、呕吐、腹泻、皮炎及电解质紊乱等。
Epidermal growth factor receptor (EGFR) is expressed in a variety of solid tumors and is closely related to the occurrence and development of tumors. necitumumab is a fully human IgG1_K monoclonal antibody that competes with epidermal growth factor for binding sites and blocks epidermal growth factor binding to its receptor and inhibits the growth of EGFR-dependent tumors. necitumumab has been approved by the U.S. Food and Drug Administration for the combination of gemcitabine and cisplatin for first-line treatment of metastatic squamous non-small cell lung cancer. Common adverse reactions include rash, vomiting, diarrhea, dermatitis and electrolyte disorders.